Novonesis (Novozymes) A/S
Research Novonesis (Novozymes) A/S (NSIS-B) on Bullrun: valuation model: 4.5% overvalued, market cap DKK 194.05B, P/E 41.0, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNSIS-B
- ExchangeCO
- CountryDenmark
- SectorBasic Materials
- IndustrySpecialty Chemicals
- CurrencyDKK
- Valuation signal4.5% overvalued
- Market capDKK 194.05B
- P/E41.0
- Dividend yield1.0%
- Financial periodQ2 2026
- RevenueEUR 1.12B
- Net incomeEUR 171.70M
- Gross margin55.7%
Valuation Snapshot
Bullrun's latest valuation model marks Novonesis (Novozymes) A/S as 4.5% overvalued; latest market cap is DKK 194.05B; P/E is 41.0; dividend yield is 1.0%.
Peer valuation comparison
Latest P/E is 40.99x versus a Basic Materials sector median of 16.68x (145.7% above).
Latest dividend yield is 0.96% versus a Basic Materials sector median of 2.3% (58.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 4.16B | EUR 583.60M | EUR 811.70M | 53.9% | 1.25 | EUR 275.30M | EUR 2.92B | EUR 10.92B |
| FY2024 | EUR 3.83B | EUR 305.80M | EUR 681.60M | 47.2% | 0.67 | EUR 280.00M | EUR 1.27B | EUR 11.23B |
| FY2023 | EUR 2.40B | EUR 407.90M | EUR 308.00M | 54.3% | 1.46 | EUR 149.70M | EUR 1.49B | EUR 1.93B |
| FY2022 | EUR 2.36B | EUR 495.32M | EUR 167.44M | 54.6% | 1.77 | EUR 139.70M | EUR 486.31M | EUR 1.91B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-03 | DKK 194.05B | 41.0 | 1.6% | 6.6 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 6.6 DKK, yield 1.0%.
| Year | Dividends/share |
|---|---|
| FY2025 | 6.45 EUR |
| FY2024 | 4 EUR |
| FY2023 | 10.2 EUR |
| FY2022 | 5.5 EUR |
About Novonesis (Novozymes) A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel;
ETFs that hold Novonesis (Novozymes) A/S
Novonesis (Novozymes) A/S is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| State Street SPDR MSCI Europe Materials UCITS ETF | 3.15% | 0.18% |
| Xtrackers Nordic Net Zero Pathway Paris Aligned UCITS ETF 1C | 3.04% | 0.15% |
| VanEck Sustainable Future of Food UCITS ETF A USD Acc | 5.31% | 0.45% |
Related stock research
Other Basic Materials stocks
Frequently asked questions
Is Novonesis (Novozymes) A/S overvalued or undervalued?
Bullrun's valuation model currently marks Novonesis (Novozymes) A/S as 4.5% overvalued.
What is Novonesis (Novozymes) A/S's market cap?
Novonesis (Novozymes) A/S's market capitalization is DKK 194.05B.
What is Novonesis (Novozymes) A/S's P/E ratio?
Novonesis (Novozymes) A/S's price-to-earnings (P/E) ratio is 41.0.
Does Novonesis (Novozymes) A/S pay a dividend?
Novonesis (Novozymes) A/S has a dividend yield of 1.0%.
What does Novonesis (Novozymes) A/S do?
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition.